Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result.
Welsing
P M J
PM
Severens
J L
JL
Laan
R F J M
RF
D000911:Antibodies, Monoclonal / Q000191:economics*; D018501:Antirheumatic Agents / Q000191:economics*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D006801:Humans; D000069285:Infliximab; D017059:Models, Econometric; D012107:Research Design
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab